Monopar Therapeutics (MNPR) Competitors $35.87 +0.71 (+2.02%) Closing price 01:04 PM EasternExtended Trading$35.87 0.00 (0.00%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. CMRX, CDMO, ORIC, QURE, AVXL, IMNM, GYRE, PHAT, VIR, and CRONShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Chimerix (CMRX), Avid Bioservices (CDMO), Oric Pharmaceuticals (ORIC), uniQure (QURE), Anavex Life Sciences (AVXL), Immunome (IMNM), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Vir Biotechnology (VIR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Chimerix Avid Bioservices Oric Pharmaceuticals uniQure Anavex Life Sciences Immunome Gyre Therapeutics Phathom Pharmaceuticals Vir Biotechnology Cronos Group Monopar Therapeutics (NASDAQ:MNPR) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Does the media refer more to MNPR or CMRX? In the previous week, Monopar Therapeutics had 8 more articles in the media than Chimerix. MarketBeat recorded 8 mentions for Monopar Therapeutics and 0 mentions for Chimerix. Monopar Therapeutics' average media sentiment score of 0.95 beat Chimerix's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Monopar Therapeutics Positive Chimerix Neutral Which has better valuation and earnings, MNPR or CMRX? Monopar Therapeutics has higher earnings, but lower revenue than Chimerix. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.48-10.31Chimerix$212K3,778.71-$82.10M-$0.99-8.63 Is MNPR or CMRX more profitable? Chimerix's return on equity of -50.78% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -55.39% -51.53% Chimerix N/A -50.78%-44.94% Do analysts recommend MNPR or CMRX? Monopar Therapeutics currently has a consensus target price of $56.50, suggesting a potential upside of 57.51%. Chimerix has a consensus target price of $8.53, suggesting a potential downside of 0.08%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Monopar Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, MNPR or CMRX? Monopar Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500. Do institutionals and insiders have more ownership in MNPR or CMRX? 1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 13.1% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryMonopar Therapeutics beats Chimerix on 8 of the 14 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$215.01M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-10.3121.5627.4020.04Price / SalesN/A281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book3.987.518.085.67Net Income-$15.59M-$55.05M$3.16B$248.47M7 Day Performance2.46%3.16%2.12%2.90%1 Month Performance11.71%5.92%4.43%5.75%1 Year Performance919.90%5.82%35.62%21.36% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics3.2035 of 5 stars$35.87+2.0%$56.50+57.5%+876.7%$215.01MN/A-10.3110CMRXChimerix0.7511 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.7159 of 5 stars$12.50+0.1%$12.25-2.0%+86.5%$799.18M$139.91M-5.23320News CoverageHigh Trading VolumeORICOric Pharmaceuticals4.1723 of 5 stars$10.00+7.4%$19.17+91.7%+41.6%$793.44MN/A-5.3580QUREuniQure1.9788 of 5 stars$13.95-1.8%$37.82+171.1%+256.1%$778.36M$27.12M-3.18500News CoverageAVXLAnavex Life Sciences3.7311 of 5 stars$9.30+2.3%$44.00+373.1%+155.9%$776.03MN/A-16.9140News CoveragePositive NewsIMNMImmunome2.543 of 5 stars$8.74-0.1%$23.33+167.0%-26.2%$761.36M$10.94M-2.7540Positive NewsGYREGyre Therapeutics0.087 of 5 stars$7.77-3.7%N/A-35.4%$756.62M$105.76M388.6940PHATPhathom Pharmaceuticals3.5995 of 5 stars$9.47-9.1%$17.50+84.8%-13.1%$727.46M$55.25M-1.81110High Trading VolumeVIRVir Biotechnology3.3603 of 5 stars$5.05-3.4%$32.86+550.6%-38.6%$722.98M$74.21M-1.20580News CoverageInsider TradeCRONCronos Group2.3128 of 5 stars$1.87+0.5%N/A-11.9%$717.37M$117.61M14.39450News Coverage Related Companies and Tools Related Companies Chimerix Alternatives Avid Bioservices Alternatives Oric Pharmaceuticals Alternatives uniQure Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Gyre Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Vir Biotechnology Alternatives Cronos Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts